Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized open-label study of utidelone versus docetaxel in platinum-failed advanced or metastatic non-small cell lung cancer
CTR20222991Phase 3Active
- Sponsor
- 成都华昊中天药业有限公司
- Start
- Dec 2022
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of utidelone in non-small cell lung cancer (NSCLC) (2 arms), sponsored by 成都华昊中天药业有限公司. Primary endpoint: overall survival. Started Dec 2022; status: active.
02
Drugs
utidelone
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20222991.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222991.